Subscribe

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. (000999.SZ)

CNY25.20 +0.32 (+1.29%)
CN SHZ Healthcare Drug Manufacturers - Specialty & Generic
Address Guanlan High-tech Park 518110
Shenzhen, CN
CEO Wen Duo Wu
Website 999.com.cn
IPO 2000-03-09
ISIN CNE0000011K8

Explore sections of this company profile

Description

China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. is a prominent pharmaceutical enterprise engaged in the research, development, manufacturing, and distribution of medicinal products. Its operations span both the People's Republic of China and international markets, additionally providing various health-related services. The company's extensive product line includes a wide range of over-the-counter (OTC) medications addressing common conditions such as colds, skin issues, gastrointestinal complaints, coughs, and needs in orthopedics and pediatrics. It also provides prescription drugs, with a focus on areas like traditional Chinese medicine, oncology, cardiovascular and cerebrovascular health, digestive system disorders, orthopedics, and pediatrics. Further offerings comprise Chinese medicine injections, specialized formula granules, and anti-infective agents. These products are often marketed under popular brand families, notably 999 family medicine, Sanjiuweitai series, 999 Ganmaoling series, and 999 dermatitis series. Founded in 1999 and headquartered in Shenzhen, PRC, the company initially operated as Sanjiu Pharmaceutical Co., Ltd. before rebranding to its current name in February 2010. It functions as a subsidiary under the umbrella of China Resources (Holdings) Co., Ltd.

Market Cap & Enterprise Value
Merger & Acquisition History

No mergers or acquisitions recorded for this company.

Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary Loading…
Indicator 1D1W2W3W1M
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
Averages
Trend
Price
Levels
Draw
CNY25.20 +0.32 (+1.29%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
11M
Beta
0.08
Float Shares
609.97M
Free Float %
36.7%
Price Performance
1D5D1M3M6M YTD1Y3Y5Y10YMax
+0.99% -0.73% -6.18% -15.34% -12.99% -14.09% -25.73% -38.94% +58.56% +86.93% +1,519.21%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
vs.
Loading histogram data…

Revenue flow

Revenue by geography

Revenue by segment

From To

Revenue composition

From To

By product

By geography

Financial Statements

Income Statement

Balance Sheet

Cash Flow Statement

Key Metrics

Financial Ratios

Employees

Financial Growth (CAGR)

Market Data

Price Targets & DCF
Current price
25.20
DCF (Unlevered) 104.98 +316.6%
DCF (Levered) 252.32 +901.3%

DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.

Ratings Trend (MoM) 92% Bullish
Rating 2026-05 Change
Strong Buy 4 0
Buy 7 0
Hold 0 0
Sell 1 0
Strong Sell 0 0
Quality scores
Altman Z-Score
2.91
Grey zone
Piotroski F-Score
7 / 9
Strong
MOAT Score
7 / 10
Strong MOAT
Composite Rating
A-
Overall Score
4 / 5
High
DCF Score
5 / 5
High
ROE Score
4 / 5
High
ROA Score
4 / 5
High
D/E Score
2 / 5
Medium
P/E Score
2 / 5
Medium
P/Book Score
3 / 5
Medium
Operational MOAT
✗ Below peers
  • ✓
    Revenue growth Drug Manufacturers - Specialty & Generic: +6.8%
    +14.4% ★ Q1'26: +18.6% (vs Q1'25)
  • ✓
    EPS growth Drug Manufacturers - Specialty & Generic: +16.5%
    +2.0% Q1'26: -14.5% (vs Q1'25)
  • ✓
    FCF margin FCF growth · Drug Manufacturers - Specialty & Generic: +32.3%
    +12.7% Q1'26: +10.1% (vs Q1'25)
  • ✗
    EBIT margin Drug Manufacturers - Specialty & Generic: +13.0%
    +15.4% ★ Q1'26: +18.6% (vs Q1'25)
  • ✗
    ROIC Drug Manufacturers - Specialty & Generic: +6.5%
    +11.8% ★ Q1'26: +11.9% (vs Q1'25)
  • ✓
    Share dilution Drug Manufacturers - Specialty & Generic: +0.0%
    -0.2% ★ Q1'26: -0.2% (vs Q1'25)
  • ✓
    Debt / EBITDA Net debt/EBITDA · Drug Manufacturers - Specialty & Generic: -0.10×
    1.17× ★ Q1'26: 1.09× (vs Q1'25)
Valuation Multiples From To
Price Forecast (3Y) From To
Model
Adjust
P/E
Theoretical Return — If Invested Today

* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.

DCF Interactive Model (UFCF)
Projection years:
Market assumptions
▶ WACC components (optional)
Ke (Cost of Equity) = Rf + β (0.12) × ERP
WACC = 86% × Ke + 14% × Kd (4.1%) × (1−t)

Modifying these values recalculates WACC automatically.

Business assumptions
—
Intrinsic value (base): 106.15 Current price: 25.20
Enterprise Value: — Equity Value: — Terminal Value: — TV as % of EV: —

Base values reflect the latest available data for this company and market conditions.

Consensus Estimates
Metric Dec 2015
actual 		Dec 2016
actual 		Dec 2017
actual 		Dec 2018
actual 		Dec 2019
actual 		Dec 2020
actual 		Dec 2021
actual 		Dec 2022
actual 		Dec 2023
actual 		Dec 2023
actual 		Dec 2024
actual 		Dec 2025
actual 		Dec 2026
2 Rev. Ana.
1 EPS Ana. 		Dec 2027
11 Rev. Ana.
2 EPS Ana. 		Dec 2028
4 Rev. Ana.
1 EPS Ana.
Revenue
7.90B
est: 8.25B (-4.2%)
8.98B
est: 9.04B (-0.7%)
11.12B
est: 10.44B (+6.5%)
13.43B
est: 13.47B (-0.3%)
14.79B
est: 14.88B (-0.6%)
13.64B
est: 14.71B (-7.3%)
16.15B
est.
15.54B
est: 17.24B (-9.8%)
18.08B
est: 25.90B (-30.2%)
24.74B
est: 25.90B (-4.5%)
27.62B
est: 27.05B (+2.1%)
31.60B
est: 31.01B (+1.9%)
34.00B
33.34B – 34.65B
+9.6% YoY
36.42B
34.78B – 37.95B
+7.1% YoY
38.83B
37.57B – 40.04B
+6.6% YoY
EBITDA
1.79B
est: 1.42B (+25.9%)
1.77B
est: 1.56B (+13.2%)
1.87B
est: 1.80B (+3.6%)
2.10B
est: 2.32B (-9.9%)
2.90B
est: 2.57B (+12.8%)
2.46B
est: 2.54B (-3.2%)
2.79B
est.
2.89B
est: 2.98B (-2.9%)
3.45B
est: 4.47B (-22.8%)
4.53B
est: 4.47B (+1.2%)
5.32B
est: 5.01B (+6.1%)
5.50B
est: 5.74B (-4.3%)
6.30B
6.18B – 6.42B
+9.6% YoY
6.75B
6.44B – 7.03B
+7.1% YoY
7.19B
6.96B – 7.42B
+6.6% YoY
EBIT
1.56B
est: 1.20B (+29.4%)
1.48B
est: 1.32B (+12.3%)
1.55B
est: 1.52B (+1.5%)
1.75B
est: 1.97B (-11.2%)
2.56B
est: 2.17B (+17.9%)
2.07B
est: 2.15B (-3.8%)
2.36B
est.
2.46B
est: 2.52B (-2.3%)
2.99B
est: 3.78B (-21.1%)
3.84B
est: 3.78B (+1.5%)
4.68B
est: 4.34B (+7.8%)
4.86B
est: 4.97B (-2.3%)
5.45B
5.35B – 5.56B
+9.6% YoY
5.84B
5.58B – 6.09B
+7.1% YoY
6.23B
6.03B – 6.42B
+6.6% YoY
Net Income
1.25B
est: 1.23B (+1.5%)
1.20B
est: 1.00B (+19.8%)
1.30B
est: 1.05B (+24.1%)
1.43B
est: 1.12B (+27.7%)
2.10B
est: 1.65B (+26.9%)
1.60B
est: 1.40B (+13.9%)
1.57B
est.
2.06B
est: 1.87B (+9.9%)
2.45B
est: 2.24B (+9.3%)
2.85B
est: 2.24B (+27.3%)
3.37B
est: 3.33B (+1.0%)
3.42B
est: 3.36B (+1.8%)
3.72B
3.56B – 3.87B
+10.6% YoY
4.09B
3.98B – 4.20B
+10.1% YoY
4.47B
4.28B – 4.65B
+9.3% YoY
SGA
3.39B
est: 2.35B (+44.5%)
4.13B
est: 2.57B (+60.7%)
5.36B
est: 2.97B (+80.3%)
7.15B
est: 3.83B (+86.7%)
7.51B
est: 4.23B (+77.4%)
5.91B
est: 4.18B (+41.2%)
4.59B
est.
5.97B
est: 4.90B (+21.8%)
6.13B
est: 7.37B (-16.8%)
8.48B
est: 7.37B (+15.0%)
8.86B
est: 9.39B (-5.6%)
11.00B
est: 10.76B (+2.3%)
11.80B
11.57B – 12.03B
+9.6% YoY
12.64B
12.07B – 13.17B
+7.1% YoY
13.48B
13.04B – 13.90B
+6.6% YoY
EPS
0.76
est: 0.96 (-21.0%)
0.72
est: 0.78 (-7.8%)
0.79
est: 0.82 (-3.5%)
0.86
est: 0.88 (-1.8%)
1.27
est: 1.29 (-1.7%)
0.96
est: 1.10 (-12.4%)
1.23
est.
1.24
est: 1.46 (-15.0%)
1.47
est: 1.75 (-16.0%)
1.72
est: 1.75 (-1.7%)
2.02
est: 2.01 (+0.6%)
2.06
est: 2.02 (+1.8%)
2.24
2.14 – 2.33
+10.6% YoY
2.46
2.40 – 2.53
+10.1% YoY
2.69
2.58 – 2.80
+9.3% YoY
Historical Ratings (3M)
Date Rating Overall DCF ROE ROA D/E P/E P/B
2026-05-29 A- 4/5 5/5 4/5 4/5 2/5 2/5 3/5
2026-05-28 A- 4/5 5/5 4/5 4/5 2/5 2/5 3/5
2026-05-27 A- 4/5 5/5 4/5 4/5 2/5 2/5 3/5
2026-05-26 A- 4/5 5/5 4/5 4/5 2/5 2/5 3/5
2026-05-25 A- 4/5 5/5 4/5 4/5 2/5 2/5 3/5
2026-05-22 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-21 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-20 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-19 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-18 A- 4/5 5/5 4/5 5/5 2/5 2/5 3/5
2026-05-15 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-14 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-05-13 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-12 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-11 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-08 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-07 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-05-06 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-04-30 A- 4/5 5/5 4/5 4/5 2/5 3/5 3/5
2026-04-29 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-28 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-27 A 4/5 5/5 4/5 5/5 2/5 3/5 3/5
2026-04-24 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-23 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-22 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-21 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-20 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-17 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5
2026-04-16 A- 4/5 5/5 4/5 5/5 1/5 3/5 3/5

Owner Earnings

Owner's Earnings (history) From To
Owner alignment
Owner's Earnings TTM
6.06B
OE per share TTM
3.62
Owner's Yield
14.90%
Maintenance CapEx ratio
2.23%
Maint CapEx / Avg PPE
20.4%

Ownership Overview

Ownership breakdown

Ownership breakdown not available.

At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
0
Beneficial owners (>5%)

No beneficial ownership filings recorded.

Institutional Activity (13F)

Institutional ownership trend

Institutional history not available.

Top institutional holders

Top holders not available.

ETF Ownership

Top ETFs holding this stock Held by 130 ETFs in our universe
# ETF Weight Est. AUM exposure TER
1 KraneShares MSCI All China Health Care Index ETF KURE 1.00% 798.4K 0.79%
2 HSBC MSCI China A UCITS ETF HMCT.L 0.14% 193.7K 0.30%
3 JPMorgan ETFs (Ireland) ICAV - China A Research Enhanced Index Equity Active UCITS ETF JREC.L 0.11% 25.5K 0.40%
4 JPMorgan Diversified Return Emerging Markets Equity ETF JPEM 0.10% 397.8K 0.44%
5 iShares MSCI China A UCITS ETF CNYE.MI 0.08% 78.6K 0.45%
6 iShares MSCI China A UCITS ETF CNYA.L 0.08% 2.38M 0.40%
7 iShares MSCI China A ETF CNYA 0.08% 179.2K 0.60%
8 Xtrackers MSCI China A UCITS ETF 1C XX2D.L 0.07% 102.1K 0.35%
9 Amundi MSCI China A UCITS ETF Acc CNAA.L 0.07% 103.6K 0.35%
10 Xtrackers Harvest CSI 300 China A-Shares ETF ASHR 0.07% 946.8K 0.65%

Insider Activity

Insider Activity — Latest Quarter

No insider activity available.

Insider buys vs sells (history)

Insider history not available.

Recent insider transactions

No recent insider transactions.

Executive team

Top executives
EBIT / Employee
242.6K
Shares Outstanding
1.66B

Executive compensation

Executive compensation (annual)

Executive compensation not available.

CEO compensation breakdown

No CEO compensation history available.

Proxy statements

Proxy statements (DEF 14A)

No proxy statements available for this company yet.

Recent SEC filings

Recent SEC filings

No SEC filings available for this company yet.

Executive team

NameTitleCompensationGender
Hui Zhou Vice President, General Counsel, Chief Compliance Officer & Director — female
Jian Xing Chief Financial Officer & Secretary of the Board — male
Ke Wang Vice President — male
Liang Wang Vice President — male
Wen Duo Wu President & Director — male
Yi Mai Vice President — male
ESG Score History

No data available for this company.

Senate Trading Activity

No Senate trading activity found for this company.

House Trading Activity

No House trading activity found for this company.

Market share among peers
Peer comparison — filtered group (TTM)
Your opinion

Share your view on this stock and instantly see how the community has voted over the last 6 months.

These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

Dividend yield history

Dividend history

Earnings history

Earnings reports

Stock splits

Related companies

Largest companies in Drug Manufacturers - Specialty & Generic